<DOC>
	<DOCNO>NCT01676584</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled study evaluate safety , tolerability , pharmacokinetics pharmacodynamics RO6811135 healthy volunteer . Subjects randomize cohort receive either single ascending dos RO6811135 placebo subcutaneously .</brief_summary>
	<brief_title>A Study Single Dose RO6811135 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male female volunteer , 18 45 year age inclusive Body mass index ( BMI ) 2232 kg/m2 inclusive Females childbearing potential male female partner childbearing potential must agree use adequate contraception define protocol History presence clinically relevant disease disorder History drug hypersensitivity food allergy Significant infection know inflammatory process screen Day 1 Any history alcohol and/or drug abuse addiction Alcohol consumption 14 unit ( 1 unit = 10 mL pure alcohol ) per week Smoking 5 cigarette day equivalent amount tobacco Positive hepatitis B , hepatitis C HIV infection Participation investigational drug device study within 3 month prior screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>